| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/BRAIN/AWM203 |
| P8608 | Fatcat ID | release_ntdtx5mh2jet7mdzxykgck2h74 |
| P698 | PubMed publication ID | 17728357 |
| P50 | author | Hannelore Ehrenreich | Q1575862 |
| Klaus-Armin Nave | Q15823700 | ||
| Anna-Leena Sirén | Q18224131 | ||
| Walter Paulus | Q66317630 | ||
| Ralf Gold | Q99630149 | ||
| P2093 | author name string | Benjamin Fischer | |
| Michael Stiefel | |||
| Claudia Bartels | |||
| Christine Norra | |||
| Nike Stender | |||
| Felix Schellenberger | |||
| P2860 | cites work | Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) | Q22241644 |
| Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury | Q24530090 | ||
| Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress | Q24611053 | ||
| The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations | Q28180426 | ||
| Multiple sclerosis | Q28214785 | ||
| A novel endogenous erythropoietin mediated pathway prevents axonal degeneration | Q28579124 | ||
| Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production | Q31859314 | ||
| A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects | Q33628316 | ||
| Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. | Q34132516 | ||
| Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial | Q34182887 | ||
| Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models | Q34325318 | ||
| Secondary progressive multiple sclerosis: current knowledge and future challenges | Q34503137 | ||
| Erythropoietin: novel approaches to neuroprotection in human brain disease | Q35956310 | ||
| Effects of erythropoietin on brain function | Q36052901 | ||
| Emerging biological roles for erythropoietin in the nervous system | Q36146959 | ||
| Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis | Q36299392 | ||
| Managing erythropoietin hyporesponsiveness | Q36427439 | ||
| The brain erythropoietin system and its potential for therapeutic exploitation in brain disease | Q36455213 | ||
| Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. | Q36457107 | ||
| In vivo evidence that erythropoietin protects neurons from ischemic damage | Q36477827 | ||
| The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration | Q36610350 | ||
| Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury | Q37250532 | ||
| Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin | Q38403090 | ||
| The role of erythropoietin in regulating angiogenesis | Q40494744 | ||
| Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. | Q40705789 | ||
| Development of a multiple sclerosis functional composite as a clinical trial outcome measure | Q40810823 | ||
| Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo | Q41559138 | ||
| A potential role for erythropoietin in focal permanent cerebral ischemia in mice. | Q42473313 | ||
| The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis | Q44695275 | ||
| Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. | Q45086893 | ||
| Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. | Q45188750 | ||
| Erythropoietin treatment improves neurological functional recovery in EAE mice | Q45266659 | ||
| Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis | Q48475566 | ||
| Recombinant erythropoietin down-regulates IL-6 and CXCR4 genes in TNF-alpha-treated primary cultures of human microvascular endothelial cells: implications for multiple sclerosis | Q48957653 | ||
| The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin | Q48962012 | ||
| Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. | Q53913927 | ||
| Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. | Q54128490 | ||
| Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin | Q59264389 | ||
| P433 | issue | Pt 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| erythropoietin | Q218706 | ||
| chronic progressive multiple sclerosis | Q18971609 | ||
| P304 | page(s) | 2577-2588 | |
| P577 | publication date | 2007-08-29 | |
| P1433 | published in | Brain | Q897386 |
| P1476 | title | Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis | |
| P478 | volume | 130 |
| Q28068709 | A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives |
| Q86566727 | A double-blind, placebo-controlled trial of adding erythropoietin to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin |
| Q88201024 | A pilot study of the effect of intravenous erythropoetin on improvement of visual function in patients with recent indirect traumatic optic neuropathy |
| Q50916632 | A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. |
| Q34109028 | Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. |
| Q34982719 | Antidepressant-like effects of erythropoietin: a focus on behavioural and hippocampal processes |
| Q41136886 | Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies |
| Q36283435 | Common variants of the genes encoding erythropoietin and its receptor modulate cognitive performance in schizophrenia |
| Q38829895 | Concordance of Several Subcellular Interactions Initiates Alzheimer's Dementia: Their Reversal Requires Combination Treatment |
| Q64914346 | Contradictory effects of erythropoietin on inhibitory synaptic transmission in left and right prelimbic cortex of mice. |
| Q89747410 | Delaying memory decline: different options and emerging solutions |
| Q42415945 | Diagnosis of infectious or inflammatory psychosyndromes |
| Q38142030 | Disease-modifying treatments for progressive multiple sclerosis |
| Q34258204 | Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder |
| Q48476592 | Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study |
| Q39711804 | Effects of erythropoietin on memory-relevant neurocircuitry activity and recall in mood disorders |
| Q58609028 | Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial |
| Q36800398 | Endogenous erythropoietin as part of the cytokine network in the pathogenesis of experimental autoimmune encephalomyelitis |
| Q48135959 | Epo is involved in angiogenesis in human glioma |
| Q37098040 | Erythropoietic agents and the elderly |
| Q39131288 | Erythropoietin (EPO) increases myelin gene expression in CG4 oligodendrocyte cells through the classical EPO receptor. |
| Q51149238 | Erythropoietin accelerates functional recovery after moderate sciatic nerve crush injury. |
| Q33907747 | Erythropoietin action in stress response, tissue maintenance and metabolism |
| Q34063671 | Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-β in macrophages |
| Q64093623 | Erythropoietin and Friedreich Ataxia: Time for a Reappraisal? |
| Q55262379 | Erythropoietin as an add-on treatment for cognitive side effects of electroconvulsive therapy: a study protocol for a randomized controlled trial. |
| Q48133730 | Erythropoietin attenuates motor neuron programmed cell death in a burn animal model |
| Q39644014 | Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice |
| Q44821543 | Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis |
| Q21245342 | Erythropoietin enhances hippocampal long-term potentiation and memory |
| Q28477706 | Erythropoietin enhances nerve repair in anti-ganglioside antibody-mediated models of immune neuropathy |
| Q37797743 | Erythropoietin for the treatment of subarachnoid hemorrhage: a review. |
| Q33479749 | Erythropoietin improves operant conditioning and stability of cognitive performance in mice |
| Q35891811 | Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study |
| Q48232589 | Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients |
| Q47937442 | Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial |
| Q34501237 | Erythropoietin prevents PC12 cells from beta-amyloid-induced apoptosis via PI3K⁄Akt pathway |
| Q28580949 | Erythropoietin promotes Schwann cell migration and assembly of the provisional extracellular matrix by recruiting beta1 integrin to the cell surface |
| Q28573061 | Erythropoietin receptor expression is concordant with erythropoietin but not with common beta chain expression in the rat brain throughout the life span |
| Q42377441 | Erythropoietin reduces experimental autoimmune encephalomyelitis severity via neuroprotective mechanisms. |
| Q36066188 | Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke |
| Q37938732 | Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression |
| Q42922791 | Erythropoietin: a multimodal neuroprotective agent |
| Q35949322 | Erythropoietin: still on the neuroprotection road |
| Q36846925 | Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients. |
| Q30475059 | Expression of constitutively active erythropoietin receptor in pyramidal neurons of cortex and hippocampus boosts higher cognitive functions in mice |
| Q90170517 | Functional hypoxia drives neuroplasticity and neurogenesis via brain erythropoietin |
| Q57477426 | GSK3β: a plausible mechanism of cognitive and hippocampal changes induced by erythropoietin treatment in mood disorders? |
| Q48592362 | High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial |
| Q49586559 | How to pursue EPO in MS. |
| Q36893279 | Immunohistochemical and transcriptome analyses indicate complex breakdown of axonal transport mechanisms in canine distemper leukoencephalitis |
| Q38345573 | Interplay between endothelin and erythropoietin in astroglia: the role in protection against hypoxia |
| Q37818329 | Intranasal erythropoietin therapy in nervous system disorders |
| Q28388335 | Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases |
| Q42762679 | Is erythropoietin a worthy candidate for traumatic brain injury or are we heading the wrong way? |
| Q59128812 | Leukemia inhibitory factor inhibits erythropoietin-induced myelin gene expression in oligodendrocytes |
| Q59800414 | Metabolic, Mental and Immunological Effects of Normoxic and Hypoxic Training in Multiple Sclerosis Patients: A Pilot Study |
| Q48060571 | Neural correlates of improved executive function following erythropoietin treatment in mood disorders |
| Q22241472 | Neurodegeneration in multiple sclerosis: novel treatment strategies |
| Q21129480 | Neuroplasticity and the next wave of antidepressant strategies |
| Q37419064 | Neuroprotection and neuroregeneration in multiple sclerosis |
| Q38129748 | Neuroprotection in multiple sclerosis: a therapeutic approach |
| Q38140727 | New strategies in the management of Guillain-Barré syndrome. |
| Q28570180 | Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons |
| Q89397480 | Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview |
| Q30496995 | Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing |
| Q29030703 | Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives |
| Q34504572 | Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward? |
| Q54975778 | Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson's Disease. |
| Q41173431 | Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple Sclerosis |
| Q37705741 | Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial |
| Q38432879 | Recombinant human erythropoietin in amyotrophic lateral sclerosis: a pilot study of safety and feasibility |
| Q36950700 | Recovery of function in humans: cortical stimulation and pharmacological treatments after stroke |
| Q30833366 | Revisiting adult neurogenesis and the role of erythropoietin for neuronal and oligodendroglial differentiation in the hippocampus |
| Q46074741 | Sex-dependent regulation of hypoxic ventilation in mice and humans is mediated by erythropoietin |
| Q34725972 | Survival and proliferative roles of erythropoietin beyond the erythroid lineage |
| Q45927294 | Survival, neuron-like differentiation and functionality of mesenchymal stem cells in neurotoxic environment: the critical role of erythropoietin. |
| Q36545939 | TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury |
| Q38986871 | The Neuroprotective Effect of Erythropoietin on Rotenone-Induced Neurotoxicity in SH-SY5Y Cells Through the Induction of Autophagy |
| Q35642010 | The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study |
| Q30463376 | The hematopoietic cytokine granulocyte-macrophage colony stimulating factor is important for cognitive functions |
| Q36484443 | Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis |
| Q41859996 | Therapeutic effects of erythropoietin on histological and functional outcomes following traumatic brain injury in rats are independent of hematocrit |
| Q37358669 | Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system |
| Q91907660 | Time to revisit oligodendrocytes in multiple sclerosis |
| Q40292313 | Transfection of primary brain capillary endothelial cells for protein synthesis and secretion of recombinant erythropoietin: a strategy to enable protein delivery to the brain |
| Q49546137 | Traumatic optic neuropathy treatment trial (TONTT): open label, phase 3, multicenter, semi-experimental trial. |
| Q91866864 | Whole-Brain Exploratory Analysis of Functional Task Response Following Erythropoietin Treatment in Mood Disorders: A Supervised Machine Learning Approach |
| Q87447444 | [New aspects in the therapy of multiple sclerosis and optic neuritis] |
Search more.